We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Feb 2023 - 18 Feb 2023

Fully Absorbable Stent Treats Coronary Artery Disease

By HospiMedica International staff writers
Posted on 18 Jul 2016
Print article
Image: The Absorb bioabsorbable drug-eluting stent (Photo courtesy of Abbott Vascular).
Image: The Absorb bioabsorbable drug-eluting stent (Photo courtesy of Abbott Vascular).
A new absorbable stent for treating coronary artery disease (CAD) releases everolimus to limit the growth of scar tissue.

The Absorb GT1 Bioresorbable Vascular Scaffold System (BVS) is made of a biodegradable poly-L-lactic acid (PLLA) and a poly-D,L-lactide (PDLLA) polymer coating that controls the release of the anti-proliferative drug everolimus. Once the vessel can remain open without the extra support, the stent is designed to slowly metabolize and eventually be resorbed by the body over a period of three years, leaving behind an intact vessel with the potential to flex, pulse, and dilate in response to various demands on the heart.

After absorption, there are only four small platinum markers left embedded in the walls of the artery, which help cardiologists identify where the Absorb GT1 BVS was originally placed. The dissolvable stent is delivered via the proprietary GlideTrack catheter, which is designed for optimal access in difficult anatomies. The Absorb GT1 BVS and GlideTrack catheter are products of Abbott Vascular (Santa Clara, CA, USA), and have been approved by the U.S. Food and Drug Administration (FDA).

“Abbott's goal is to help people everywhere live better, fuller and healthier lives,” said Deepak Nath, PhD, senior vice president of Abbott Vascular. “The Absorb bioresorbable stent treats coronary artery disease without committing people to a permanent metal implant, giving them peace of mind and helping them get back to their daily lives without the concern of having a permanent metallic implant.”

“This novel technology appeals to both physicians and patients alike, because after treating the underlying blockage it is completely absorbed, leaving nothing behind,” said Gregg Stone, MD, of Columbia University Medical Center (CUMC, New York, NY, USA). “No metal means the treated artery can pulse and flex naturally as demands on the heart change with everyday activities. No metal may also reduce the potential of future blockages that occur with permanent metallic stents, and allows easier access to other treatment options should they prove necessary in the patient's future.”

Everolimus is a derivative of sirolimus and functions as an inhibitor of mammalian target of rapamycin (mTOR). It is currently used as an immunosuppressant to prevent rejection of organ transplants and stents and as a treatment of renal cell cancer and other tumors.

Related Links:
Abbott Vascular

Gold Supplier
Ultrasound Transducer/Probe Cleaner
Transeptic Cleaning Solution
Double-Door Pass-Through Autoclave
150L - 700L Double-Door / Pass-Through
Portable Medical Air Compressor
Handheld POC Ultrasound

Print article



view channel
Image: MyoVista Wavelet technology utilizes AI for early detection of heart disease (Photo courtesy of Heart Test Laboratories)

Novel ECG Technology Utilizes AI for Early Detection of Heart Disease

Cardiovascular disease is responsible for 17.9 million deaths every year, or about 32% of all deaths worldwide. Every week, millions of electrocardiographs (ECGs) are performed across the world, making... Read more

Critical Care

view channel
Image: Studies have shown the Autus Valve maintains control of blood flow as it expands (Photo courtesy of Boston Children’s Hospital)

Heart Valve That Grows Along With Child Could Reduce Invasive Surgeries

In children with congenital pulmonary valve disease, the flow of blood between the heart and lungs is impeded. In cases where the pulmonary valves have narrowed or are leaking and cannot be treated effectively... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Point of Care

view channel
Image: Steripath improves the diagnostic accuracy and timeliness of sepsis test results (Photo courtesy of Magnolia)

All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. However, positive blood culture results can be frequently wrong, and about... Read more


view channel
Image: The global patient positioning systems market is projected to reach USD 1.7 billion by 2027 (Photo courtesy of Pexels)

Global Patient Positioning Systems Market Driven by Increasing Chronic Diseases

The global patient positioning systems market is projected to grow at a CAGR of 4% from USD 1.4 billion in 2022 to USD 1.7 billion by 2027, driven by increasing technological advancements in medical devices,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.